Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 127, Issue 3, Pages 739-749Publisher
SPRINGER
DOI: 10.1007/s10549-010-1243-y
Keywords
Adjuvant therapy; Breast cancer; Cost-effectiveness; Gene diagnosis; 21-Gene signature
Categories
Funding
- Japan's Ministry of Health, Labour and Welfare [H18-3JIGAN-IPPAN-007]
- Japan's Ministry of Education, Culture, Sports, Science and Technology [22590451]
- Grants-in-Aid for Scientific Research [22590451] Funding Source: KAKEN
Ask authors/readers for more resources
The 21-gene signature is validated as a good predictor of recurrence for lymph node-negative/positive, hormone receptor-positive, early-stage breast cancer in Japanese patient population. This study evaluates the cost-effectiveness of two scenarios designed to include the assay into Japan's social health insurance benefit package: one for LN-, ER+, ESBC and another for LN-/+, ER+, ESBC. An economic decision tree and Markov model under Japan's health system from the societal perspective is constructed with new evidence from the Japanese validation study. Incremental cost-effectiveness ratios are estimated as Ayen384,828 (US$3,848) per QALY for the indication for LN- scenario and Ayen568,533 (US$5,685) per QALY for the indication for LN-/+ scenario. Both are not more than the suggested social willingness-to-pay for one QALY gain from an innovative medical intervention in Japan, Ayen5,000,000/QALY (US$50,000/QALY). Sensitivity analyses show that this result is plausibly robust, since ICERs do not exceed the threshold by various changes of assumptions made and values employed. In conclusion, the inclusion of the assay in Japan's social health insurance benefit package for not only LN- diseases but also LN+ diseases is cost-effective. Such a decision can be justifiable as an efficient use of finite resources for health care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available